TABLE 1.
Patient characteristics for all studies as well as for a subgroup of patients with BTV above 1 ml which were included in the PET evaluation.
| All included patients | Evaluated patients (BTV > 1 ml) | |
| Characteristic | PET/MRI studies (No. of patients) | PET/MRI studies (#patients) |
| n | 318 (194) | 222 (147) |
| Male | 173 (105) | 121 (82) |
| Female | 145 (89) | 101 (65) |
| Anaplastic pilocytic astrocytoma | 3 (2) | 3 (2) |
| Anaplastic pleomorphic xanthoastrocytoma | 2 (1) | 2 (1) |
| Astrocytoma, WHO grade 3 | 36 (23) | 19 (13) |
| Glioblastoma, WHO grade 4 | 229 (138) | 171 (115) |
| Oligodendroglioma, WHO grade 2 | 11 (5) | 8 (3) |
| Oligodendroglioma, WHO grade 3 | 21 (16) | 14 (9) |
| Other* | 16 (9) | 5 (4) |
*Other include patients with pleomorphic xanthoastrocytoma, diffuse midline glioma H3 K27M mutant and more. Molecular characteristics are not included as they are not essential to this study.